RESULTS FROM A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS WITH PD-L1 UNSELECTED METASTATIC 2ND LINE HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

1Antonio López Pousa*, 2Enriqueta Felip, 3Martin Forster, 4Bernard Doger, 5Patricia Rodburgh, 6Julio Peguero, 7Enric Carcereny, 8Enric Triebel. 1Hospital Sant Pau, Barcelona, Spain; 2Vall d’Hebron University Hospital, Hospital, Barcelona, Spain; 3UCL Cancer Institute/NHS Foundation, London, UK; 4START Madrid- Fundación Jiménez Diaz, Madrid, Spain; 5Beatson West of Scotland Cancer Center, Glasgow, UK; 6Tasman Oncology, Queensland, Australia; 7Oncology Consultants, P. A., Houston, TX, USA; 8Catalan Institute of Oncology Badalona, Badalona, Spain; 9Christie NHS Foundation Trust, Manchester, UK; 10Clinical Development, Immutep GmbH, Berlin, Germany; 11Research and Development, Immutep S.A.S., Chatenay Malabry, France

Background Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MHC class II, thus mediating antigen presenting cell (APC) and CD8 T-cell activation. Such stimulation of the dendritic cell network and resulting T cell recruitment by efti may lead to stronger anti-tumor responses than observed with pembrolizumab alone. We hereby report results of the 2nd line metastatic head and neck squamous cell carcinoma (HNSCC) cohort (part C) of the TACTI-002 phase II trial (NCT03625323).

Methods Eligible patients (pts) with HNSCC, unselected for PD-L1 expression with disease progression on or after 1st line platinum-based therapy, received 30 mg subcutaneous efti Q2W for 24 weeks and 200 mg pembrolizumab Q3W for up to 2 years or until disease progression. The study used a Simon’s 2-stage design with objective response rate (ORR) as the primary endpoint (EP). Secondary EPs included tolerability, progression free survival (PFS), overall survival (OS), pharmacokinetics, pharmacodynamics, and immunogenicity. Tumor response was assessed Q9W. PD-L1 was assessed centrally (22C3 clone). The study was approved by ethic committees and institutional review boards.

Results Between Mar 2019 and Jan 2021, 39 pts were enrolled (cut-off Apr 2021). The median age was 62 yrs (range 37–84) with 90% male pts. ECOG was 0 and 1 in 33% and 67%, respectively. Primary tumor location at diagnosis was oropharynx (36%), oral cavity (31%), hypopharynx (18%) and larynx (15%) with all PD-L1 subgroups (CPS< 1, to £ 19; £ 20) being represented. All pts were pre-treated with platinum-based chemotherapy. Thirty-seven (37) pts were evaluated for response with ORR (iRECIST) of 30% (95% CI 16–47%) with 5 (14%) CRs; 6 (16%) PRs; 3 (8%) SDs; 17 (46%) PDs and 6 (16%) pts not evaluable. Median PFS was 2.1 months and 30% were progression-free at 6 months. One patient (3%) discontinued due to pembro-related adverse event. The most common (>10%) treatment emergent adverse events were hypothyroidism (21%), cough (18%), asthenia (15%), fatigue (13%), anemia (13%), diarrhea (13%) and weight decreased (13%).

Conclusions Efti in combination with pembrolizumab is safe, showing encouraging antitumor activity in platinum pre-treated, 2nd line HNSCC patients. For further investigation of this combination, a 1st line HNSCC trial (NCT04811027) has been initiated.

Trial Registration NCT03625323

Ethics Approval The study was approved by relevant ethic committees and institutional review boards

http://dx.doi.org/10.1136/jitc-2021-SITC2021.359